Novartis’ Newly Licensed Antidepressant Hits Snag In EU Under Separate Sponsor
This article was originally published in The Pink Sheet Daily
Executive Summary
EMEA’s review committee recommends against authorization of agomelatine, but sides with Gardasil and Champix/Chantix.